Jane Katharine Osbourne

Title: Jane Katharine Osbourne: Innovator in Cancer Research

Introduction

Jane Katharine Osbourne is a notable inventor based in Cambridge, GB. She has made significant contributions to the field of cancer research, particularly through her innovative work on specific binding members for human carcinoembryonic antigen (CEA). Her research has implications for targeted cancer therapies.

Latest Patents

Jane holds a patent for "Specific binding members, materials and methods." This patent describes specific binding members for human carcinoembryonic antigen (CEA) that comprise a human antibody antigen binding domain. The specific binding members may have a dissociation constant of less than 1.0 × 10^-8 M and are designed to be substantially non-crossreactive with human liver and other normal tissues. They may specifically target the A3-B3 extracellular domain of CEA and a carbohydrate epitope of CEA. These binding members can be produced through recombinant expression from encoding nucleic acid and can be modified in various ways according to known techniques. CEA is recognized as a tumor antigen, and the specific binding members have demonstrated the ability to bind and target CEA both in vitro and in vivo.

Career Highlights

Throughout her career, Jane has worked with esteemed organizations such as the Medical Research Council and Cambridge Antibody Technology Limited. Her work has been pivotal in advancing the understanding and treatment of cancer.

Collaborations

Jane has collaborated with notable colleagues, including Deborah J Allen and John Gerald McCafferty, contributing to a rich environment of innovation and research.

Conclusion

Jane Katharine Osbourne's contributions to cancer research through her patented innovations highlight her role as a leading inventor in the field. Her work continues to influence the development of targeted therapies for cancer treatment.